DOI . ORG {}

Matching Content Categories {📚}

• Education
• Insurance
• Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🚄 Respectable Traffic: 10k - 20k visitors per month


Based on our best estimate, this website will receive around 10,420 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We find it hard to spot revenue streams.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

secukinumab, patients, week, placebo, study, asas, treatment, groups, article, group, response, baseline, weeks, efficacy, dose, pubmed, google, scholar, endpoints, safety, data, ankylosing, spondylitis, period, primary, improvement, rates, antitnf, arthritis, intravenous, additional, reported, measure, subcutaneous, assessment, secondary, included, file, observed, therapy, results, criteria, previous, trial, table, van, analysis, active, loading, placebocontrolled,

Topics {✒️}

high-sensitivity c-reactive protein springer nature ethics declarations anti–interleukin-17a monoclonal antibody author information authors abbreviations acr line biologic therapy treatment-emergent anti-drug antibodies state privacy rights discussion fully human antibody eu/ctr-search/search steroidal anti-inflammatory drugs previous anti-tnf therapy il-23-il-17 axis long-term results conclusions secukinumab mixed-model repeated measures perez-de-lis anti-tnf response status family-wise error rate /united_states/enbrel/derm/enbrel_pi il-17a receptor biologics-induced autoimmune diseases anti-tnf therapy independent ethics committees interleukin-17a inhibitor methods van der heijde ricardo blanco de jong emgj dose-dependent drug exposure van den bosch ankylosing spondylitis flare tumor necrosis factor obscured dose-dependent differences rights exposure-adjusted incidence rate gov/ct2/show/nct02008916 exposure-adjusted incidence rates privacy choices/manage cookies conclusions biologic treatment author correspondence original author novartis pharma ag authors scientific editing active ankylosing spondylitis anti-tnf status entire treatment period

Questions {❓}

• The concept of spondyloarthritis: where are we now?
• Eu/ctr-search/search?
• Gov/ct2/show/NCT02008916?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
         description:Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or matched placebo. Patients in the placebo group were re-randomized to subcutaneous secukinumab at a dose of 300 or 150 mg at week 16. The primary endpoint was the Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response rate at week 16 in the IV-300 mg or IV-150 mg versus placebo. Other endpoints assessed through week 52 included improvements in ASAS40, ASAS 5/6, Bath Ankylosing Spondylitis Disease Activity Index, and ASAS partial remission responses, as well as the change from baseline in high-sensitivity C-reactive protein levels. Statistical analyses followed a predefined hierarchical hypothesis testing strategy to adjust for multiplicity of testing, with non-responder imputation used for binary variables and mixed-model repeated measures for continuous variables. The primary efficacy endpoint was met; the ASAS20 response rate was significantly greater at week 16 in the IV-300 mg (60.5%; P < 0.01) and IV-150 mg (58.1%; P < 0.05) groups versus placebo (36.8%). All secondary endpoints were met at week 16, except ASAS partial remission in the IV-150 mg group. Improvements achieved with secukinumab in all clinical endpoints at week 16 were also sustained at week 52. Infections, including candidiasis, were more common with secukinumab than with placebo during the placebo-controlled period. During the entire treatment period, pooled incidence rates of Candida infections and grade 3–4 neutropenia were 1.8% for both of these adverse events in secukinumab-treated patients. Secukinumab (300 mg and 150 mg dose groups) provided rapid, significant and sustained improvement through 52 weeks in the signs and symptoms of patients with AS. The safety profile was consistent with previous reports, with no new or unexpected findings. ClinicalTrials.gov, NCT02008916 . Registered on 8 December 2013. EUDRACT 2013-001090-24. Registered on 24 October 2013). The study was not retrospectively registered.
         datePublished:2017-12-22T00:00:00Z
         dateModified:2017-12-22T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13075-017-1490-y
         keywords:
            Secukinumab
            IL-17
            Ankylosing spondylitis
            Biologic therapy
            Rheumatology
            Orthopedics
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_Fig2_HTML.gif
         isPartOf:
            name:Arthritis Research & Therapy
            issn:
               1478-6362
            volumeNumber:19
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Karel Pavelka
               url:http://orcid.org/0000-0002-9324-1377
               affiliation:
                     name:Charles University
                     address:
                        name:Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Alan Kivitz
               affiliation:
                     name:Altoona Center for Clinical Research
                     address:
                        name:Altoona Center for Clinical Research, Duncansville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva Dokoupilova
               affiliation:
                     name:Medical Plus, s.r.o.
                     address:
                        name:Medical Plus, s.r.o., Uherske Hradiste, Czech Republic
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ricardo Blanco
               affiliation:
                     name:Hospital Universitario Marqués de Valdecilla
                     address:
                        name:Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marco Maradiaga
               affiliation:
                     name:Centro de Investigación de Tratamientos Innovadores de Sinaloa
                     address:
                        name:Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, México
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hasan Tahir
               affiliation:
                     name:Barts Health NHS Trust
                     address:
                        name:Barts Health NHS Trust, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luminita Pricop
               affiliation:
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mats Andersson
               affiliation:
                     name:Novartis Pharma AG
                     address:
                        name:Novartis Pharma AG, Basel, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aimee Readie
               affiliation:
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brian Porter
               affiliation:
                     name:Novartis Pharmaceuticals Corporation
                     address:
                        name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
      description:Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or matched placebo. Patients in the placebo group were re-randomized to subcutaneous secukinumab at a dose of 300 or 150 mg at week 16. The primary endpoint was the Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response rate at week 16 in the IV-300 mg or IV-150 mg versus placebo. Other endpoints assessed through week 52 included improvements in ASAS40, ASAS 5/6, Bath Ankylosing Spondylitis Disease Activity Index, and ASAS partial remission responses, as well as the change from baseline in high-sensitivity C-reactive protein levels. Statistical analyses followed a predefined hierarchical hypothesis testing strategy to adjust for multiplicity of testing, with non-responder imputation used for binary variables and mixed-model repeated measures for continuous variables. The primary efficacy endpoint was met; the ASAS20 response rate was significantly greater at week 16 in the IV-300 mg (60.5%; P < 0.01) and IV-150 mg (58.1%; P < 0.05) groups versus placebo (36.8%). All secondary endpoints were met at week 16, except ASAS partial remission in the IV-150 mg group. Improvements achieved with secukinumab in all clinical endpoints at week 16 were also sustained at week 52. Infections, including candidiasis, were more common with secukinumab than with placebo during the placebo-controlled period. During the entire treatment period, pooled incidence rates of Candida infections and grade 3–4 neutropenia were 1.8% for both of these adverse events in secukinumab-treated patients. Secukinumab (300 mg and 150 mg dose groups) provided rapid, significant and sustained improvement through 52 weeks in the signs and symptoms of patients with AS. The safety profile was consistent with previous reports, with no new or unexpected findings. ClinicalTrials.gov, NCT02008916 . Registered on 8 December 2013. EUDRACT 2013-001090-24. Registered on 24 October 2013). The study was not retrospectively registered.
      datePublished:2017-12-22T00:00:00Z
      dateModified:2017-12-22T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13075-017-1490-y
      keywords:
         Secukinumab
         IL-17
         Ankylosing spondylitis
         Biologic therapy
         Rheumatology
         Orthopedics
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_Fig2_HTML.gif
      isPartOf:
         name:Arthritis Research & Therapy
         issn:
            1478-6362
         volumeNumber:19
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Karel Pavelka
            url:http://orcid.org/0000-0002-9324-1377
            affiliation:
                  name:Charles University
                  address:
                     name:Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Alan Kivitz
            affiliation:
                  name:Altoona Center for Clinical Research
                  address:
                     name:Altoona Center for Clinical Research, Duncansville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva Dokoupilova
            affiliation:
                  name:Medical Plus, s.r.o.
                  address:
                     name:Medical Plus, s.r.o., Uherske Hradiste, Czech Republic
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ricardo Blanco
            affiliation:
                  name:Hospital Universitario Marqués de Valdecilla
                  address:
                     name:Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marco Maradiaga
            affiliation:
                  name:Centro de Investigación de Tratamientos Innovadores de Sinaloa
                  address:
                     name:Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, México
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hasan Tahir
            affiliation:
                  name:Barts Health NHS Trust
                  address:
                     name:Barts Health NHS Trust, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luminita Pricop
            affiliation:
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mats Andersson
            affiliation:
                  name:Novartis Pharma AG
                  address:
                     name:Novartis Pharma AG, Basel, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aimee Readie
            affiliation:
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brian Porter
            affiliation:
                  name:Novartis Pharmaceuticals Corporation
                  address:
                     name:Novartis Pharmaceuticals Corporation, East Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Arthritis Research & Therapy
      issn:
         1478-6362
      volumeNumber:19
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Charles University
      address:
         name:Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
         type:PostalAddress
      name:Altoona Center for Clinical Research
      address:
         name:Altoona Center for Clinical Research, Duncansville, USA
         type:PostalAddress
      name:Medical Plus, s.r.o.
      address:
         name:Medical Plus, s.r.o., Uherske Hradiste, Czech Republic
         type:PostalAddress
      name:Hospital Universitario Marqués de Valdecilla
      address:
         name:Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
         type:PostalAddress
      name:Centro de Investigación de Tratamientos Innovadores de Sinaloa
      address:
         name:Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, México
         type:PostalAddress
      name:Barts Health NHS Trust
      address:
         name:Barts Health NHS Trust, London, UK
         type:PostalAddress
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
      name:Novartis Pharma AG
      address:
         name:Novartis Pharma AG, Basel, Switzerland
         type:PostalAddress
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
      name:Novartis Pharmaceuticals Corporation
      address:
         name:Novartis Pharmaceuticals Corporation, East Hanover, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Karel Pavelka
      url:http://orcid.org/0000-0002-9324-1377
      affiliation:
            name:Charles University
            address:
               name:Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Alan Kivitz
      affiliation:
            name:Altoona Center for Clinical Research
            address:
               name:Altoona Center for Clinical Research, Duncansville, USA
               type:PostalAddress
            type:Organization
      name:Eva Dokoupilova
      affiliation:
            name:Medical Plus, s.r.o.
            address:
               name:Medical Plus, s.r.o., Uherske Hradiste, Czech Republic
               type:PostalAddress
            type:Organization
      name:Ricardo Blanco
      affiliation:
            name:Hospital Universitario Marqués de Valdecilla
            address:
               name:Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
               type:PostalAddress
            type:Organization
      name:Marco Maradiaga
      affiliation:
            name:Centro de Investigación de Tratamientos Innovadores de Sinaloa
            address:
               name:Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, México
               type:PostalAddress
            type:Organization
      name:Hasan Tahir
      affiliation:
            name:Barts Health NHS Trust
            address:
               name:Barts Health NHS Trust, London, UK
               type:PostalAddress
            type:Organization
      name:Luminita Pricop
      affiliation:
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
      name:Mats Andersson
      affiliation:
            name:Novartis Pharma AG
            address:
               name:Novartis Pharma AG, Basel, Switzerland
               type:PostalAddress
            type:Organization
      name:Aimee Readie
      affiliation:
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
      name:Brian Porter
      affiliation:
            name:Novartis Pharmaceuticals Corporation
            address:
               name:Novartis Pharmaceuticals Corporation, East Hanover, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
      name:Altoona Center for Clinical Research, Duncansville, USA
      name:Medical Plus, s.r.o., Uherske Hradiste, Czech Republic
      name:Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
      name:Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, México
      name:Barts Health NHS Trust, London, UK
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA
      name:Novartis Pharma AG, Basel, Switzerland
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA
      name:Novartis Pharmaceuticals Corporation, East Hanover, USA

Social Networks {👍}(2)

• https://twitter.com/biomedcentral
• https://www.facebook.com/BioMedCentral

External Links {🔗}(244)

• What's the monthly money flow for https://www.biomedcentral.com/privacy-statement?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#main-content's financial summary
• How much money does https://www.biomedcentral.com generate?
• How much cash flow does https://www.biomedcentral.com/journals have monthly?
• How much income does https://www.biomedcentral.com/getpublished have?
• Get to know https://www.biomedcentral.com/about's earnings
• Monthly income for https://www.biomedcentral.com/account
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/ generate?
• How profitable is https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/about?
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles generate?
• What are the earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/submission-guidelines?
• What's the financial gain of https://submission.nature.com/new-submission/13075/3?
• What are the earnings of https://arthritis-research.biomedcentral.com/counter/pdf/10.1186/s13075-017-1490-y.pdf?
• How profitable is https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Karel-Pavelka-Aff1 pull in monthly?
• How much does https://orcid.org/0000-0002-9324-1377 gross monthly?
• What's the monthly money flow for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff1?
• How much profit does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Alan-Kivitz-Aff2 generate?
• How much money does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff2 generate?
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Eva-Dokoupilova-Aff3 produce monthly?
• What's the total monthly financial gain of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff3?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Ricardo-Blanco-Aff4's financial summary
• Check the income stats for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff4
• How much income is https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Marco-Maradiaga-Aff5 earning monthly?
• How much income does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff5 have?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Hasan-Tahir-Aff6's revenue stream
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff6 pull in monthly?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Luminita-Pricop-Aff7 rake in every month?
• Monthly income for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff7
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Mats-Andersson-Aff8 make?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Aff8 income
• What's the income generated by https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Aimee-Readie-Aff7 each month?
• Earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#auth-Brian-Porter-Aff7
• What's the financial outcome of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#citeas?
• How much money does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/metrics generate?
• What's the revenue for https://clinicaltrials.gov/ct2/show/NCT02008916?
• Explore the financials of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR1
• See how much https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR2 makes per month
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR3 bring in?
• What's the total monthly financial gain of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR4?
• Income figures for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR5
• What's the income of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR6?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR7 gross monthly?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR8 bring in each month?
• Learn how profitable https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR9 is on a monthly basis
• How much income is https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR10 earning monthly?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR11 generate monthly?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR12 make?
• What's the total monthly financial gain of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#ref-CR12?
• What is the earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#ref-CR13?
• How much profit does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#ref-CR14 make?
• Earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR15
• Profit of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR16
• See how much https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#ref-CR17 makes per month
• Find out how much https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#ref-CR18 earns monthly
• How much cash flow does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR19 have monthly?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR14 net monthly?
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#MOESM1 generate?
• Learn how profitable https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#Fig1 is on a monthly basis
• How profitable is https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#Tab1?
• What is the monthly revenue of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/figures/1?
• What is the monthly revenue of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/tables/1?
• Earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR20
• Financial intake of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#Fig2
• Explore the financials of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/figures/2
• Learn how profitable https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#Tab2 is on a monthly basis
• What's the monthly income of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/tables/2?
• What's the profit of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#Tab3?
• How much income does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/tables/3 have?
• What's the monthly money flow for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#MOESM2?
• Find out how much https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#MOESM3 earns monthly
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR21 generate?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#MOESM4's total income per month
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#Tab4's revenue stream
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y/tables/4's total income per month
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR22 pull in?
• What's the revenue for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR17?
• What's the financial outcome of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR18?
• What's the financial outcome of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR23?
• Financial intake of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR24
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR25 net monthly?
• How much profit does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR26 generate?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR27's revenue stream
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#ref-CR28 bring in?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21684383 gross monthly?
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Spondyloarthritis&journal=Lancet&doi=10.1016%2FS0140-6736%2811%2960071-8&volume=377&issue=9783&pages=2127-37&publication_year=2011&author=Dougados%2CM&author=Baeten%2CD?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25488776
• How much does http://scholar.google.com/scholar_lookup?&title=The%20concept%20of%20spondyloarthritis%3A%20where%20are%20we%20now%3F&journal=Best%20Pract%20Res%20Clin%20Rheumatol&doi=10.1016%2Fj.berh.2014.10.007&volume=28&issue=5&pages=663-72&publication_year=2014&author=Garg%2CN&author=Bosch%2CF&author=Deodhar%2CA pull in?
• What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17448825 each month?
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=Ankylosing%20spondylitis&journal=Lancet&doi=10.1016%2FS0140-6736%2807%2960635-7&volume=369&issue=9570&pages=1379-90&publication_year=2007&author=Braun%2CJ&author=Sieper%2CJ have monthly?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25193010?
• How much money does http://scholar.google.com/scholar_lookup?&title=Health-related%20quality%20of%20life%20in%20patients%20with%20ankylosing%20spondylitis%3A%20a%20comprehensive%20review&journal=Expert%20Rev%20Pharmacoecon%20Outcomes%20Res&doi=10.1586%2F14737167.2014.957679&volume=14&issue=6&pages=857-72&publication_year=2014&author=Kotsis%2CK&author=Voulgari%2CPV&author=Drosos%2CAA&author=Carvalho%2CAF&author=Hyphantis%2CT make?
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17042055's earnings
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=The%20burden%20of%20ankylosing%20spondylitis&journal=J%20Rheumatol%20Suppl&volume=78&pages=4-11&publication_year=2006&author=Boonen%2CA&author=Linden%2CSM
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=Global%20prevalence%20of%20ankylosing%20spondylitis&journal=Rheumatology%20%28Oxford%29&doi=10.1093%2Frheumatology%2Fket387&volume=53&issue=4&pages=650-7&publication_year=2014&author=Dean%2CLE&author=Jones%2CGT&author=MacDonald%2CAG&author=Downham%2CC&author=Sturrock%2CRD&author=Macfarlane%2CGJ have monthly?
• How much income does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:STN:280:DC%2BC3Mvot1emsA%3D%3D have?
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21540199
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086052 have monthly?
• How much money does http://scholar.google.com/scholar_lookup?&title=2010%20update%20of%20the%20ASAS%2FEULAR%20recommendations%20for%20the%20management%20of%20ankylosing%20spondylitis&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fard.2011.151027&volume=70&issue=6&pages=896-904&publication_year=2011&author=Braun%2CJ&author=Berg%2CR&author=Baraliakos%2CX&author=Boehm%2CH&author=Burgos-Vargas%2CR&author=Collantes-Estevez%2CE&author=Dagfinrud%2CH&author=Dijkmans%2CB&author=Dougados%2CM&author=Emery%2CP make?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18701556 make?
• How much income does http://scholar.google.com/scholar_lookup?&title=Adalimumab%20effectiveness%20for%20the%20treatment%20of%20ankylosing%20spondylitis%20is%20maintained%20for%20up%20to%202%20years%3A%20long-term%20results%20from%20the%20ATLAS%20trial&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fard.2007.087270&volume=68&issue=6&pages=922-9&publication_year=2009&author=Heijde%2CD&author=Schiff%2CMH&author=Sieper%2CJ&author=Kivitz%2CAJ&author=Wong%2CRL&author=Kupper%2CH&author=Dijkmans%2CBA&author=Mease%2CPJ&author=Davis%2CJC have?
• What's the revenue for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC2MXjtlChsLo%3D?
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25575936?
• What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Emerging%20drugs%20for%20the%20treatment%20of%20axial%20and%20peripheral%20spondyloarthritis&journal=Expert%20Opin%20Emerg%20Drugs&doi=10.1517%2F14728214.2015.993378&volume=20&issue=1&pages=1-14&publication_year=2015&author=Braun%2CJ&author=Kiltz%2CU&author=Heldmann%2CF&author=Baraliakos%2CX?
• Explore the financials of https://link.springer.com/doi/10.1007/s11926-013-0356-9
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23888365?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Treatment%20challenges%20in%20axial%20spondylarthritis%20and%20future%20directions&journal=Curr%20Rheumatol%20Rep&doi=10.1007%2Fs11926-013-0356-9&volume=15&issue=9&publication_year=2013&author=Sieper%2CJ
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20649798 bring in?
• What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Switching%20from%20etanercept%20to%20adalimumab%20is%20effective%20and%20safe%3A%20results%20in%2030%20patients%20with%20psoriasis%20with%20primary%20failure%2C%20secondary%20failure%20or%20intolerance%20to%20etanercept&journal=Br%20J%20Dermatol&doi=10.1111%2Fj.1365-2133.2010.09950.x&volume=163&issue=4&pages=838-46&publication_year=2010&author=L%C3%BCmig%2CPPM&author=Lecluse%2CLLA&author=Driessen%2CRJB&author=Spuls%2CPI&author=Boezeman%2CJB&author=Kerkhof%2CPCM&author=Jong%2CEMGJ?
• Find out how much https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC2MXotVeqtrw%3D earns monthly
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25907700 have?
• What's http://scholar.google.com/scholar_lookup?&title=The%20IL-23-IL-17%20axis%20in%20inflammatory%20arthritis&journal=Nat%20Rev%20Rheumatol&doi=10.1038%2Fnrrheum.2015.53&volume=11&issue=7&pages=415-29&publication_year=2015&author=Lubberts%2CE's gross income?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26794859
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Spondyloarthropathies%3A%20IL-17A%20blockade%20ameliorates%20ankylosing%20spondylitis&journal=Nat%20Rev%20Rheumatol&doi=10.1038%2Fnrrheum.2016.7&volume=12&issue=2&publication_year=2016&author=Duarte%2CJH generate?
• How much cash flow does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsVKku7vO have monthly?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24035250?
• How profitable is http://scholar.google.com/scholar_lookup?&title=Anti-interleukin-17A%20monoclonal%20antibody%20secukinumab%20in%20treatment%20of%20ankylosing%20spondylitis%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2813%2961134-4&volume=382&issue=9906&pages=1705-13&publication_year=2013&author=Baeten%2CD&author=Baraliakos%2CX&author=Braun%2CJ&author=Sieper%2CJ&author=Emery%2CP&author=Heijde%2CD&author=McInnes%2CI&author=Laar%2CJM&author=Landewe%2CR&author=Wordsworth%2CP?
• Get to know https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlOlurjN's earnings
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26699169?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Secukinumab%2C%20an%20interleukin-17A%20inhibitor%2C%20in%20ankylosing%20spondylitis&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1505066&volume=373&issue=26&pages=2534-48&publication_year=2015&author=Baeten%2CD&author=Sieper%2CJ&author=Braun%2CJ&author=Baraliakos%2CX&author=Dougados%2CM&author=Emery%2CP&author=Deodhar%2CA&author=Porter%2CB&author=Martin%2CR&author=Andersson%2CM
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25007392 makes per month
• How much does http://scholar.google.com/scholar_lookup?&title=Secukinumab%20in%20plaque%20psoriasis%E2%80%93results%20of%20two%20phase%203%20trials&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1314258&volume=371&issue=4&pages=326-38&publication_year=2014&author=Langley%2CRG&author=Elewski%2CBE&author=Lebwohl%2CM&author=Reich%2CK&author=Griffiths%2CCE&author=Papp%2CK&author=Puig%2CL&author=Nakagawa%2CH&author=Spelman%2CL&author=Sigurgeirsson%2CB make?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtV2ltbrM make?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26135703 pull in monthly?
• http://scholar.google.com/scholar_lookup?&title=Secukinumab%2C%20a%20human%20anti-interleukin-17A%20monoclonal%20antibody%2C%20in%20patients%20with%20psoriatic%20arthritis%20%28FUTURE%202%29%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2815%2961134-5&volume=386&issue=9999&pages=1137-46&publication_year=2015&author=McInnes%2CIB&author=Mease%2CPJ&author=Kirkham%2CB&author=Kavanaugh%2CA&author=Ritchlin%2CCT&author=Rahman%2CP&author=Heijde%2CD&author=Landewe%2CR&author=Conaghan%2CPG&author=Gottlieb%2CAB's revenue stream
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC28XkslCguw%3D%3D generate monthly?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26422723 generate?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Secukinumab%20inhibition%20of%20interleukin-17A%20in%20patients%20with%20psoriatic%20arthritis&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1412679&volume=373&issue=14&pages=1329-39&publication_year=2015&author=Mease%2CPJ&author=McInnes%2CIB&author=Kirkham%2CB&author=Kavanaugh%2CA&author=Rahman%2CP&author=Heijde%2CD&author=Landewe%2CR&author=Nash%2CP&author=Pricop%2CL&author=Yuan%2CJ
• What's the monthly money flow for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC2cXltFKhs70%3D?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23361084 make?
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20secukinumab%2C%20a%20fully%20human%20anti-interleukin-17A%20monoclonal%20antibody%2C%20in%20patients%20with%20moderate-to-severe%20psoriatic%20arthritis%3A%20a%2024-week%2C%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%20II%20proof-of-concept%20trial&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fannrheumdis-2012-202646&volume=73&issue=2&pages=349-56&publication_year=2014&author=McInnes%2CIB&author=Sieper%2CJ&author=Braun%2CJ&author=Emery%2CP&author=Heijde%2CD&author=Isaacs%2CJD&author=Dahmen%2CG&author=Wollenhaupt%2CJ&author=Schulze-Koops%2CH&author=Kogan%2CJ is on a monthly basis
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20926833
• How much profit does http://scholar.google.com/scholar_lookup?&title=Effects%20of%20AIN457%2C%20a%20fully%20human%20antibody%20to%20interleukin-17A%2C%20on%20psoriasis%2C%20rheumatoid%20arthritis%2C%20and%20uveitis&journal=Sci%20Transl%20Med&doi=10.1126%2Fscitranslmed.3001107&volume=2&publication_year=2010&author=Hueber%2CW&author=Patel%2CDD&author=Dryja%2CT&author=Wright%2CAM&author=Koroleva%2CI&author=Bruin%2CG&author=Antoni%2CC&author=Draelos%2CZ&author=Gold%2CMH&author=Durez%2CP make?
• How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27741340 have monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Secukinumab%20self-administration%20by%20prefilled%20syringe%20maintains%20reduction%20of%20plaque%20psoriasis%20severity%20over%2052%20weeks%3A%20results%20of%20the%20FEATURE%20trial&journal=J%20Drugs%20Dermatol&volume=15&issue=10&pages=1226-34&publication_year=2016&author=Gottlieb%2CAB&author=Blauvelt%2CA&author=Prinz%2CJC&author=Papanastasiou%2CP&author=Pathan%2CR&author=Nyirady%2CJ&author=Fox%2CT&author=Papavassilis%2CC pull in?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25488787 gross monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Treatment%20of%20spondyloarthritis%20beyond%20TNF-alpha%20blockade&journal=Best%20Pract%20Res%20Clin%20Rheumatol&doi=10.1016%2Fj.berh.2014.10.019&volume=28&issue=5&pages=819-27&publication_year=2014&author=Bosch%2CF&author=Deodhar%2CA earn?
• What's the profit of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BD2MXotFWkt74%3D?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15983902
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Tumor%20necrosis%20factor%20inhibition%20and%20invasive%20fungal%20infections&journal=Clin%20Infect%20Dis&doi=10.1086%2F430000&volume=41&issue=Suppl%203&pages=S208-12&publication_year=2005&author=Filler%2CSG&author=Yeaman%2CMR&author=Sheppard%2CDC?
• What's the income generated by https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/cas-redirect/1:CAS:528:DC%2BC38XhslKgsbrI each month?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23114587's financial summary
• Get to know http://scholar.google.com/scholar_lookup?&title=Biologics-induced%20autoimmune%20diseases&journal=Curr%20Opin%20Rheumatol&doi=10.1097%2FBOR.0b013e32835b1366&volume=25&issue=1&pages=56-64&publication_year=2013&author=Perez-Alvarez%2CR&author=Perez-de-Lis%2CM&author=Ramos-Casals%2CM's earnings
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17729297 generate?
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=Biologic%20treatment%20of%20rheumatoid%20arthritis%20and%20the%20risk%20of%20malignancy%3A%20analyses%20from%20a%20large%20US%20observational%20study&journal=Arthritis%20Rheum&doi=10.1002%2Fart.22864&volume=56&issue=9&pages=2886-95&publication_year=2007&author=Wolfe%2CF&author=Michaud%2CK have monthly?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19289296
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Adalimumab-induced%20neutropenia%20in%20a%20patient%20with%20rheumatoid%20arthritis&journal=Joint%20Bone%20Spine&doi=10.1016%2Fj.jbspin.2008.09.017&volume=76&issue=3&pages=312-3&publication_year=2009&author=Ottaviani%2CS&author=Cerf-Payrastre%2CI&author=Kemiche%2CF&author=Pertuiset%2CE generate?
• What's the income generated by http://www.rxabbvie.com/pdf/humira.pdf each month?
• How much does http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf earn?
• Explore the financials of https://citation-needed.springer.com/v2/references/10.1186/s13075-017-1490-y?format=refman&flavour=references
• How much does https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001090-24 net monthly?
• How much does https://clinicaltrials.gov/ct2/show/NCT02008916?term=CAIN457F2314&rank=1 bring in each month?
• How profitable is https://www.biomedcentral.com/search?query=author%23Karel%20Pavelka?
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Karel%20Pavelka's total income per month
• What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Karel%20Pavelka%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much profit does https://www.biomedcentral.com/search?query=author%23Alan%20Kivitz generate?
• How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alan%20Kivitz making per month?
• What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alan%20Kivitz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Financial intake of https://www.biomedcentral.com/search?query=author%23Eva%20Dokoupilova
• What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eva%20Dokoupilova?
• What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eva%20Dokoupilova%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.biomedcentral.com/search?query=author%23Ricardo%20Blanco make?
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ricardo%20Blanco have monthly?
• What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ricardo%20Blanco%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• https://www.biomedcentral.com/search?query=author%23Marco%20Maradiaga's financial summary
• What's https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marco%20Maradiaga's gross income?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marco%20Maradiaga%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• What is the monthly revenue of https://www.biomedcentral.com/search?query=author%23Hasan%20Tahir?
• Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hasan%20Tahir
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hasan%20Tahir%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
• How much does https://www.biomedcentral.com/search?query=author%23Luminita%20Pricop bring in each month?
• What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Luminita%20Pricop?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Luminita%20Pricop%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the monthly money flow for https://www.biomedcentral.com/search?query=author%23Mats%20Andersson?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mats%20Andersson bring in each month?
• What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mats%20Andersson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
• Learn about the earnings of https://www.biomedcentral.com/search?query=author%23Aimee%20Readie
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Aimee%20Readie pull in?
• Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Aimee%20Readie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://www.biomedcentral.com/search?query=author%23Brian%20Porter's total income per month
• How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brian%20Porter bring in?
• How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brian%20Porter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/mailto:[email protected]'s total income per month
• Income figures for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#MOESM5
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/articles/10.1186/s13075-017-1490-y#MOESM6 rake in every month?
• https://static-content.springer.com/esm/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_MOESM1_ESM.pdf's financial summary
• What's the total monthly financial gain of https://static-content.springer.com/esm/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_MOESM2_ESM.docx?
• How much does https://static-content.springer.com/esm/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_MOESM3_ESM.docx generate monthly?
• What's the monthly money flow for https://static-content.springer.com/esm/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_MOESM4_ESM.pdf?
• How much profit does https://static-content.springer.com/esm/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_MOESM5_ESM.docx make?
• How much revenue does https://static-content.springer.com/esm/art%3A10.1186%2Fs13075-017-1490-y/MediaObjects/13075_2017_1490_MOESM6_ESM.docx bring in?
• Get to know http://creativecommons.org/licenses/by/4.0/'s earnings
• How much does http://creativecommons.org/publicdomain/zero/1.0/ gross monthly?
• How much income does https://s100.copyright.com/AppDispatchServlet?title=Efficacy%2C%20safety%2C%20and%20tolerability%20of%20secukinumab%20in%20patients%20with%20active%20ankylosing%20spondylitis%3A%20a%20randomized%2C%20double-blind%20phase%203%20study%2C%20MEASURE%203&author=Karel%20Pavelka%20et%20al&contentID=10.1186%2Fs13075-017-1490-y©right=The%20Author%28s%29.&publication=1478-6362&publicationDate=2017-12-22&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY%20%2B%20CC0 have?
• Income figures for https://crossmark.crossref.org/dialog/?doi=10.1186/s13075-017-1490-y
• Discover the revenue of https://citation-needed.springer.com/v2/references/10.1186/s13075-017-1490-y?format=refman&flavour=citation
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/search?query=Secukinumab&facet-discipline="Medicine%20%26%20Public%20Health" pull in?
• What are the earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/search?query=IL-17&facet-discipline="Medicine%20%26%20Public%20Health"?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/search?query=Ankylosing%20spondylitis&facet-discipline="Medicine%20%26%20Public%20Health" net monthly?
• https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/search?query=Biologic%20therapy&facet-discipline="Medicine%20%26%20Public%20Health"'s financial summary
• What's the income of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Abs1?
• Check the income stats for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Sec1
• How much profit does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Sec2 generate?
• How much profit is https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Sec7 making per month?
• How much income is https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Sec15 earning monthly?
• What's the financial gain of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Sec16?
• How much revenue does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#abbreviations produce monthly?
• What's the income of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Bib1?
• What's the total monthly financial gain of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Ack1?
• How much money does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#author-information make?
• What's the financial outcome of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#ethics?
• What's the financial intake of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Sec17?
• How much profit does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#rightslink make?
• See how much https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#article-info makes per month
• Income figures for https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Fig1
• What's the financial gain of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/figures/1?
• Earnings of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/#Fig2
• How much cash flow does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/figures/2 have monthly?
• How much revenue does https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:STN:280:DC%2BC3Mvot1emsA%3D%3D produce monthly?
• Learn how profitable https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXjtlChsLo%3D is on a monthly basis
• What's https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXotVeqtrw%3D's gross income?
• Revenue of https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsVKku7vO
• Learn how profitable https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlOlurjN is on a monthly basis
• How much profit does https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtV2ltbrM make?
• How much does https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC28XkslCguw%3D%3D make?
• How much profit does https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXltFKhs70%3D generate?
• https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXotFWkt74%3D income
• How much does https://arthritis-research.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhslKgsbrI earn?
• What's the income of https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/mailto:[email protected]?
• What's https://blogs.biomedcentral.com/'s gross income?
• How profitable is https://www.biomedcentral.com/login?
• Revenue of https://authorservices.springernature.com/go/sn/?utm_source=Website&utm_medium=BMC&utm_campaign=SNAS+Referrals+2022&utm_id=ref2022
• How much cash flow does https://www.biomedcentral.com/about/policies have monthly?
• How much does https://www.biomedcentral.com/accessibility pull in monthly?
• Financial intake of https://www.biomedcentral.com/about/press-centre
• How much cash flow does https://support.biomedcentral.com/support/home have monthly?
• Discover the revenue of https://biomedcentral.typeform.com/to/VLXboo
• How much does https://www.biomedcentral.com/about/jobs earn?
• How much profit does http://www.weibo.com/biomedcentral generate?
• How much does https://www.biomedcentral.com/terms-and-conditions make?
• Income figures for https://www.springernature.com/ccpa
• How much revenue does https://www.biomedcentral.com/cookies bring in?
• How much does https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y/javascript:void(0); earn?
• What's the financial outcome of https://www.springernature.com?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Prism.js

Emails and Hosting {✉️}

Mail Servers:

• mx.zoho.eu
• mx2.zoho.eu
• mx3.zoho.eu

Name Servers:

• josh.ns.cloudflare.com
• zita.ns.cloudflare.com

CDN Services {📦}

• Crossref